全文获取类型
收费全文 | 69179篇 |
免费 | 6971篇 |
国内免费 | 2635篇 |
专业分类
耳鼻咽喉 | 154篇 |
儿科学 | 728篇 |
妇产科学 | 297篇 |
基础医学 | 3106篇 |
口腔科学 | 423篇 |
临床医学 | 6469篇 |
内科学 | 8682篇 |
皮肤病学 | 1144篇 |
神经病学 | 2693篇 |
特种医学 | 805篇 |
外国民族医学 | 7篇 |
外科学 | 2533篇 |
综合类 | 8681篇 |
现状与发展 | 5篇 |
一般理论 | 3篇 |
预防医学 | 4857篇 |
眼科学 | 680篇 |
药学 | 30267篇 |
41篇 | |
中国医学 | 3015篇 |
肿瘤学 | 4195篇 |
出版年
2024年 | 266篇 |
2023年 | 1323篇 |
2022年 | 2065篇 |
2021年 | 2830篇 |
2020年 | 2882篇 |
2019年 | 2752篇 |
2018年 | 2759篇 |
2017年 | 2932篇 |
2016年 | 2696篇 |
2015年 | 2695篇 |
2014年 | 4613篇 |
2013年 | 7508篇 |
2012年 | 4517篇 |
2011年 | 4633篇 |
2010年 | 3646篇 |
2009年 | 3266篇 |
2008年 | 3137篇 |
2007年 | 3128篇 |
2006年 | 2789篇 |
2005年 | 2498篇 |
2004年 | 2106篇 |
2003年 | 1935篇 |
2002年 | 1439篇 |
2001年 | 1397篇 |
2000年 | 1081篇 |
1999年 | 901篇 |
1998年 | 803篇 |
1997年 | 762篇 |
1996年 | 629篇 |
1995年 | 580篇 |
1994年 | 493篇 |
1993年 | 415篇 |
1992年 | 478篇 |
1991年 | 403篇 |
1990年 | 331篇 |
1989年 | 255篇 |
1988年 | 262篇 |
1987年 | 251篇 |
1986年 | 198篇 |
1985年 | 213篇 |
1984年 | 172篇 |
1983年 | 129篇 |
1982年 | 112篇 |
1981年 | 98篇 |
1980年 | 62篇 |
1979年 | 59篇 |
1978年 | 69篇 |
1977年 | 49篇 |
1976年 | 48篇 |
1975年 | 50篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
3.
4.
5.
《Journal of vascular and interventional radiology : JVIR》2022,33(4):359-367.e8
PurposeTo review and to compare indirectly the outcomes of minimally invasive therapies for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.Materials and MethodsA literature search via Medline and Cochrane Central databases was completed for randomized control studies published between January 2000 to April 2020 for the following therapies: Rezum, Urolift, Aquablation, and prostatic artery embolization (PAE). Data on the following variables were included: International prostate symptom score (IPSS), maximum urinary flow rate, quality of life, and postvoid residual (PVR). Standard mean differences between treatments were compared through a meta-analysis using transurethral resection of the prostate (TURP) to assess differences in treatment effect.ResultsThere was no significant difference in outcomes between therapies for IPSS at the 3, 6, and 12-month follow ups. Although outcomes for Rezum were only available out to 3 months, there were no consistently significant differences in outcomes when comparing Aquablation versus PAE versus Rezum. TURP PVR was significantly better than Urolift at 3, 6, and 12 months. No significant differences in minor or major adverse events were noted.ConclusionAlthough significant differences in outcomes were limited, Aquablation and PAE were the most durable at 12 months. PAE has been well studied on multiple randomized control trials with minimal adverse events while Aquablation has limited high quality data and has been associated with bleeding-related complications. 相似文献
6.
《Digestive and liver disease》2022,54(11):1486-1493
BackgroundCold snare polypectomy (CSP) is a promising technique for the removal of sessile serrated polyps (SSPs) ≥ 10 mm. However, the efficacy and safety of this technique remain undetermined.AimsWe aimed to comprehensively evaluate the efficacy and safety of CSP for SSPs ≥ 10 mm.MethodsPubMed, EMBASE, Web of Science and Cochrane Library were searched up to January 2021.ResultsA total of 10 studies consisting of 1727 SSPs (range, 10–40 mm) from 1021 patients were included. The overall rates of technical success, adverse events (AEs) and residual SSPs were 100%, 0.7% and 2.9%, respectively. Subgroup analysis showed that the rates of technical success and AEs were comparable between CSP and cold endoscopic mucosal resection (EMR) (99.9% vs. 100% and 1.3% vs. 0.5%, respectively), between the proximal and distal colon (100% vs. 99.9% and 0.3% vs. 0, respectively), and between polyps of 10–19 mm and ≥20 mm (99.8% vs. 100% and 0.9% vs. 0, respectively). However, subgroup analysis showed that the rate of residual SSPs was slightly lower in CSP compared with cold EMR (1.3% vs. 3.9%), as well as in polyps of 10–19 mm compared with those ≥20 mm (3.1% vs. 4.7%).ConclusionCSP was an effective and safe technique for removing SSPs ≥ 10 mm. 相似文献
7.
目的 基于文本挖掘技术和生物医学数据库对新型冠状病毒肺炎(COVID-19)相关文献进行数据挖掘分析,探究COVID-19及其主要症状发热、咳嗽、呼吸障碍相关基因靶点,筛选潜在有效的化学药和中药。方法 使用GenCLiP 3网站获取COVID-19和其主要症状咳嗽、发热、呼吸障碍共4个关键词的共有靶点,在METASCAPE数据库中对其进行基因本体(GO)和通路富集分析,再利用String数据库和Cytoscape软件构建共有靶点的蛋白质相互作用网络,筛选获得核心基因,运用DGIdb数据库、SymMap数据库针对核心基因进行中西医治疗药物预测。结果 获得COVID-19及其主要症状共有基因靶点28个,其中有IL2、IL1B、CCL2等核心基因16个,使用DGIdb数据库筛选获得与16个关键靶点相互作用的化学药包括沙利度胺、来氟米特、环孢素等28种,中药包括虎杖、黄芪、芦荟等70味。结论 COVID-19及其主要症状的病理机制可能和CD4、KNG1、VEGFA等28个共有基因相关,可能通过介导TNF、IL-17等信号通路参与COVID-19病理过程。潜在有效药物可能通过作用相关靶点通路起到治疗COVID-19的作用。 相似文献
8.
9.
Sung‐Hyun Hwang Myung‐Chul Kim Sumin Ji Yeseul Yang Yeji Jeong Yongbaek Kim 《Cancer science》2019,110(4):1256-1267
Metformin, a drug for type 2 diabetes mellitus, has shown therapeutic effects for various cancers. However, it had no beneficial effects on the survival rate of human malignant mesothelioma (HMM) patients. The present study was performed to elucidate the underlying mechanism of metformin resistance in HMM cells. Glucose‐starved HMM cells had enhanced resistance to metformin, demonstrated by decreased apoptosis and autophagy and increased cell survival. These cells showed abnormalities in mitochondria, such as decreased ATP synthesis, morphological elongation, altered mitochondrial permeability transition pore and hyperpolarization of mitochondrial membrane potential (MMP). Intriguingly, Mdr1 was significantly upregulated in mitochondria but not in cell membrane. The upregulated mitochondrial Mdr1 was reversed by treatment with carbonyl cyanide m‐chlorophenyl hydrazone, an MMP depolarization inducer. Furthermore, apoptosis and autophagy were increased in multidrug resistance protein 1 knockout HMM cells cultured under glucose starvation with metformin treatment. The data suggest that mitochondrial Mdr1 plays a critical role in the chemoresistance to metformin in HMM cells, which could be a potential target for improving its therapeutic efficacy. 相似文献
10.
Barouyr Baroudjian Dimitri Arangalage Stefania Cuzzubbo Baptiste Hervier Celeste Lebbé Gwenael Lorillon 《Expert review of anticancer therapy》2019,19(3):209-222
Introduction: Immune checkpoint inhibitors (ICI) are now a standard of care in the treatment of many cancers leading to durable responses in patients with metastatic disease. These agents are generally well tolerated but may lead to the occurrence of immune-related adverse events (irAEs). As any organ may be affected, clinicians should be aware of the broad range of clinical manifestations and symptoms and keep in mind that toxicities may occur late, at any point along a patient’s treatment course. Although the most common irAEs are rarely severe, some of them may be associated with great morbidity and even become life-threatening. The rate of occurrence, type and severity of irAEs may vary with the type of ICI; thus, grade 3 and 4 irAEs are reported in more than 55% of patients treated with the combination of ipilimumab 3 mg/kg and nivolumab 1 mg/kg.
Area covered: This review presents the management of irAEs resulting from checkpoint blockade, with a focus on rare irAEs.
Expert commentary: With the development of immuno-oncology and the expanding role of ICI, physicians have learnt to diagnose and treat most of the irAEs that can occur. This review provides an overview of current guidelines, previously published studies and our multidisciplinary team based practices. 相似文献